Alligator Bioscience Raises an Additional EUR 1.14 Million in Second Closing

Alligator Bioscience AB has announced that it has raised an additional EUR 1.14 million in a second closing of the round of equity financing. The second closing totals the financing round at EUR 6.6 million. The capital will prepare the company for a planned IPO in about 2 years.

For further information please contact:

Gun-Britt Fransson,

CEO

Tel: +46 46 286 4284.

Email: guf@alligatorbioscience.com

Or visit: www.alligatorbioscience.com.

Home > News & Events > News > Alligator Bioscience Raises an Additional EUR 1.14 Million in Second Closing
Last updated: 2007-06-13

The official Medicon Valley site is brought to you by the organisations Region Skåne and Copenhagen Capacity - in association with Medicon Valley Alliance

Contact:
Copenhagen Capacity,	tel: +45 33 22 02 22
Region Skåne,	tel: +46 (0)40 623 97 48

Alligator Bioscience AB

Alligator Bioscience AB

Alligator Bioscience AB is a biotechnology company that focuses on discovery and development of early protein drug candidates, independently and in partnership, within inflammation and cancer. Since 2001, the FIND® (Fragment INduced Diversity) technology platform has been validated by successfully...